Metsera
- Country
- Ownership
- -
- Employees
- -
- Market Cap
- -
- Introduction
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Metsera
- Target Recruit Count
- 250
- Registration Number
- NCT06973720
- Locations
- 🇺🇸
Research Site 097203-001001, Hollywood, Florida, United States
🇺🇸Research Site 097203-001003, Tampa, Florida, United States
🇺🇸Research Site 097203-001002, Decatur, Georgia, United States
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
- Conditions
- Obesity and Obesity-related Medical Conditions
- Interventions
- Drug: MET233 and MET097Drug: PlaceboDrug: MET233
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Metsera
- Target Recruit Count
- 132
- Registration Number
- NCT06924320
- Locations
- 🇺🇸
Research Site MET233/097 24-101-001, Cypress, California, United States
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
- Conditions
- Obesity in DiabetesType 2 Diabetes Mellitus (T2DM)
- Interventions
- Drug: MET097 InjectionDrug: Placebo
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Metsera
- Target Recruit Count
- 125
- Registration Number
- NCT06897202
- Locations
- 🇺🇸
Research Site 097202-001001, Hollywood, Florida, United States
🇺🇸Research Site 097202-001003, Tampa, Florida, United States
🇺🇸Research Site 097202-001002, Decatur, Georgia, United States
This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity
- Conditions
- Obesity and Overweight
- Interventions
- Biological: (Part C) MET097Biological: (Part C) Placebo
- First Posted Date
- 2025-03-04
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Metsera
- Target Recruit Count
- 262
- Registration Number
- NCT06857617
- Locations
- 🇺🇸
Research Site MET097 23-101-002, Anaheim, California, United States
🇺🇸Research Site MET097 23-101-003, Cypress, California, United States
🇺🇸Research Site MET097 23-101-001, Overland Park, Kansas, United States
A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults with Obesity or Overweight
- Conditions
- ObesityOverweight or Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Metsera
- Target Recruit Count
- 225
- Registration Number
- NCT06712836
- Locations
- 🇺🇸
Research Site MET097 24-201-002, Hollywood, Florida, United States
🇺🇸Research Site MET097 24-201-001, Anaheim, California, United States